Navigation Links
Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
Date:4/25/2011

merase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in three Phase 2b studies in patients with HCV genotypes 1 through 6 and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and one interferon free combination trial. These clinical studies are being conducted through a strategic collaboration with Roche.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities an
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... a leader in the development of Chimeric Antigen Receptors ... cancers, today announced the completion of a series A ... -based healthcare private equity fund.   CARsgen ... new therapeutics for liver, lung, stomach and brain cancers. ... Hospital, the company plans to initiate clinical studies for ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3
... 10 Sosei Group Corporation,("Sosei"; TSE Mothers Index: ... a Japanese Phase III clinical trial for the,emergency ... distribution rights to the product in Japan from ... to evaluate the safety and prevented,pregnancy rate of ...
... To Mitigate the Impact of a Disease, - ... Gala,to Raise Research Funds, HUNTINGTON BEACH, Calif., July ... prolonging the lifespan and quality,of life for people with ... body to produce thick, sticky mucus, which clogs the ...
Cached Medicine Technology:Sosei Announces Completion of Phase III Trial for NorLevo(R) 2The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis 2The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis 3
(Date:11/26/2014)... 2014 For its December issue ... AIS Report on Blue Cross and Blue Shield Plans* ... the varied strategies the two Blues plans are implementing ... treatments for sleep apnea, ranging from brick-and-mortar retail stores ... linked to increased rates of a variety of serious ...
(Date:11/26/2014)... November 26, 2014 With a redesign ... Dr. Steven Meier has enhanced the user experience ... and prospective patients an online destination for orthopedic and ... to present the new and improved version of the ... it easier than ever for current and prospective patients ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 GI for ... before seen reductions in prices of their popular nutritional ... Liposomal Vitamin D3 . Discounts of 40% will ... , GI for Life’s proprietary ColoVite supplement is a ... to promote colon health. One easy-to-take colon vitamin with ...
(Date:11/26/2014)... Sonru, the video interviewing specialist, has today announced ... Chief Marketing Officer, in addition to the formal opening ... has been appointed as Chief Operating Officer. He is ... Chief Marketing Officer. , Mr Jones is a seasoned ... senior roles with The Walt Disney Company and Adventis ...
(Date:11/26/2014)... Anthropologists have identified concrete recommendations that ... Ebola, improve international support, and pave the way ... Africa. , The report, “Strengthening West African ... Insights,” will be made public during a press ... Fri., Dec. 5, 11 a.m., at the AAA ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:GI For Life Slashes Prices by 40% on Liposomal Vitamin D3 and ColoVite Colon Health Formula for a Limited Time 2Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 2Health News:Anthropologists Release Recommendations, Better Practices to Contain Ebola 3
... HILLS, Calif., Dec. 5 With the popularity ... looking for longer,lasting alternatives to prevent facial wrinkles. ... active practice in Beverly Hills,says, "Fillers such as ... suture material. When injected into tissue, all of,these ...
... in the Annals,of Emergency Medicine ("Increasing Rates of Emergency ... to 2003") finds the rate of,elderly Americans seeking emergency ... Kenneth L. Noller, MD, President of the American College ... on behalf of the Alliance of Specialty Medicine., ...
... cardiovascular troubles by 2035 , , WEDNESDAY, Dec. 5 (HealthDay ... to be overweight or obese adults and more likely ... studies conclude. , The first, out of Denmark, found ... risk of coronary heart disease as adults. , The ...
... 5 Eastern Insurance,Holdings, Inc. (Nasdaq: EIHI ) ... has authorized a $0.05 per share quarterly cash,dividend on ... 28, 2007 to shareholders of record at the close ... parent company of Eastern Life and Health Insurance Company,("Eastern ...
... Indevus Pharmaceuticals, Inc.,(Nasdaq: IDEV ) today announced ... Conference on Thursday, December 13, 2007 at 12:30 PM,Eastern ... City. The,presentation will be web cast live and may ... website at http://www.indevus.com ., About Indevus, ...
... more complicated medical case, what makes different physicians ... Researchers at UC Davis have identified several key ... of a patients medical appointment, and ultimately with ... , In a new study, "Primary Care Visit ...
Cached Medicine News:Health News:Facial Deformity Danger? 2Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Overweight Kids Often Become Obese, Unhealthy Adults 2Health News:Overweight Kids Often Become Obese, Unhealthy Adults 3Health News:Eastern Insurance Holdings, Inc. Announces Quarterly Dividend 2Health News:Eastern Insurance Holdings, Inc. Announces Quarterly Dividend 3Health News:Indevus Pharmaceuticals To Present at RBC Capital Markets Conference 2Health News:Indevus Pharmaceuticals To Present at RBC Capital Markets Conference 3Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2
... Catheters make motility testing simpler ... catheters set up in seconds ... with every sensor circumferential, Air-Charged ... anatomical irregularities. For advanced performance ...
Manometric Calibration System for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
Medicine Products: